Janssen Korea's (Daratumumab) and Takeda Korea’s Alunbrig (Brigatinib) were included in the Price-Volume Agreement (PVA).

Otsuka Pharmaceutical Korea's "Iclusig" and AstraZeneca Korea's "Impinji" (Dubalumab) were also subject to negotiations on drug prices due to increased usage.

The NHIS recently introduced "PVA (Type Ka/Na) Monitoring Drugs for 3rd Quarter of 2021" on its website. Targets for monitoring in third quarter of this year are 173 items from 90 pharmaceutical groups.

PVA is a method shared by the NHIS and pharmaceutical companies to share the risk of health insurance finances, and the drug price will be reduced through negotiations with the NHIS.